The focal point for the 2024 Banff Course is Endocrine Pathology. This course serves as a platform for exchanging insights into the latest advancements in the field. It will cover topics crucial for practicing pathologists and trainees, encompassing comprehensive discussions on thyroid, parathyroid, pancreas, adrenal, and endocrine lesions from other sites. Renowned experts from around the globe will deliver in-depth presentations, shedding light on various aspects relevant to Endocrine Pathology, with a primary emphasis on diagnosis, including updates on nomenclature, new entities and upcoming molecular tests. Additionally, the course will spotlight pertinent aspects related to the prognosis and management of endocrine tumours and conditions, offering insights into the evolving landscape of treatment strategies and prognostic markers that may relate to the practice of pathologists.

Target Audience

This course is tailored for practicing general and anatomic pathologists, pathologist assistants, endocrine surgeons, clinicians specializing in endocrinology and oncology, as well as residents and fellows pursuing training in any of these specialties.

Platinum Sponsor Showcase

At Illumina, our mission is to improve human health by unlocking the power of the genome. Our sequencing by synthesis chemistry is used to generate high-accuracy DNA and RNA sequence data in studies around the globe. Our microarrays also provide accurate, high-throughput genotyping for a range of applications. Through innovation and collaboration, we have developed comprehensive genomic profiling tools that help investigators identify biomarkers, describe tumor biology, and inform therapy selections. The opportunity to transform tumor profiling with innovative assays, new companion diagnostics, and liquid biopsy tools inspires us to push the boundaries of what is possible and drive innovation.


Upon completion of this course, participants will be equipped to:

  • Assess and apply recent updates in endocrine pathology.
  • Identify and address complex thyroid, parathyroid, lung, GI, pancreas, and adrenal pathology lesions.
  • Demonstrate proficiency in utilizing immunohistochemistry markers to ascertain tumour diagnosis, origin and prognosis with relevant clinical, radiological and surgical correlations
  • Recognize the significance of molecular pathology in understanding and diagnosing endocrine pathology conditions.
  • Navigate challenges associated with nomenclature in lung endocrine tumours.
  • Discuss genetic syndromes relevant to endocrine pathology and their diagnostic implications.
  • Engage in case presentations and discussion of current topics in endocrine pathology

Course Directors:
Dr. Benjamin Adam
Dr. Michael Mengel
Dr. Dylan Pillai

Planning Committee Co-Chairs:
Dr. Julinor Bacani
Dr. Steven Gorombey

Planning Committee Members:
Dr. Marcia Abbott
Dr. Erin Chapman
Dr. Konstantin Koro
Dr. Remegio Maglantay
Dr. Sebastiao Martins
Dr. Adrian Sim
Dr. Emilija Todorovic

Speaker Highlights

Professor Andrew M Bellizzi, M.D.

University of Iowa Hospitals and Clinics

Professor William C. Faquin, MD, PhD

Harvard Medical School

Massachusetts Eye and Ear Infirmary

Professor Anthony J. Gill AM MD FRCPA

University of Sydney

Royal North Shore Hospital


In keeping with accreditation guidelines, speakers participating in this event have been asked to disclose to the audience any financial involvement with industry or other organizations that may potentially influence the presentation of the educational material. Disclosure may be done verbally or using a slide prior to the speaker’s presentation.


The registration information is collected under the authority of the Alberta FOIPP Act. This information is required to register you in the course, prepare the course material for your use, and will be used to notify you of other courses or pertinent information. The financial information is used to process applicable fees and is retained for future reference. This information will not be shared with any other individual or organization.